Heron Therapeutics, Inc. HRTX
Heron Therapeutics, Inc. (Nasdaq: HRTX) is a pain/anesthesia drug developer. Its lead program, ZYNRELEF (bupivacaine and meloxicam), is in Pre-clinical for Postsurgical analgesia for up to 72 hours after soft tissue and orthopedic surgery.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ZYNRELEF | Postsurgical analgesia (FDA approved May 2021; indication expanded Dec 2021 and Jan 2024) | small molecule | Approved |
| APONVIE (IV aprepitant) | Prevention of postoperative nausea and vomiting (FDA approved Sept 2022) | small molecule | Approved |
| CINVANTI (IV aprepitant) | Prevention of chemotherapy-induced nausea and vomiting (FDA approved Nov 2017) | small molecule | Approved |
| SUSTOL (extended-release granisetron) | Prevention of CINV with MEC/AC chemotherapy (FDA approved Aug 2016; to be discontinued from sale Sept 30, 2026) | small molecule | Approved |
| HTX-034 | Bupivacaine/meloxicam related candidate (named in patent section only; no clinical status stated) | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.